Systemic	systemic	O	O
toxicity	toxicity	O	S_disease
following	following	O	O
administration	administration	O	O
of	of	O	O
sirolimus	sirolimus	S_chemical	O
(	(	O	O
formerly	formerly	O	O
rapamycin	rapamycin	S_chemical	O
)	)	O	O
for	for	O	O
psoriasis	psoriasis	O	S_disease
:	:	O	O
association	association	O	O
of	of	O	O
capillary	capillary	O	B_disease
leak	leak	O	I_disease
syndrome	syndrome	O	I_disease
with	with	O	O
apoptosis	apoptosis	O	O
of	of	O	O
lesional	lesional	O	O
lymphocytes	lymphocytes	O	O
.	.	O	O

BACKGROUND	background	O	O
:	:	O	O
Sirolimus	sirolimus	S_chemical	O
(	(	O	O
formerly	formerly	O	O
rapamycin	rapamycin	S_chemical	O
)	)	O	O
is	is	O	O
an	an	O	O
immunosuppressive	immunosuppressive	O	O
agent	agent	O	O
that	that	O	O
interferes	interferes	O	O
with	with	O	O
T-cell	t-cell	O	O
activation	activation	O	O
.	.	O	O

After	after	O	O
2	2	O	O
individuals	individuals	O	O
with	with	O	O
psoriasis	psoriasis	O	S_disease
developed	developed	O	O
a	a	O	O
capillary	capillary	O	B_disease
leak	leak	O	I_disease
syndrome	syndrome	O	I_disease
following	following	O	O
treatment	treatment	O	O
with	with	O	O
oral	oral	O	O
sirolimus	sirolimus	S_chemical	O
lesional	lesional	O	O
skin	skin	O	O
cells	cells	O	O
and	and	O	O
activated	activated	O	O
peripheral	peripheral	O	O
blood	blood	O	O
cells	cells	O	O
were	were	O	O
analyzed	analyzed	O	O
for	for	O	O
induction	induction	O	O
of	of	O	O
apoptosis	apoptosis	O	O
.	.	O	O

OBSERVATIONS	observations	O	O
:	:	O	O
A	a	O	O
keratome	keratome	O	O
skin	skin	O	O
specimen	specimen	O	O
from	from	O	O
1	1	O	O
patient	patient	O	O
with	with	O	O
sirolimus-induced	sirolimus-induced	O	O
capillary	capillary	O	B_disease
leak	leak	O	I_disease
syndrome	syndrome	O	I_disease
had	had	O	O
a	a	O	O
2.3-fold	2.3-fold	O	O
increase	increase	O	O
in	in	O	O
percentage	percentage	O	O
of	of	O	O
apoptotic	apoptotic	O	O
cells	cells	O	O
(	(	O	O
to	to	O	O
48	48	O	O
%	%	O	O
)	)	O	O
compared	compared	O	O
with	with	O	O
an	an	O	O
unaffected	unaffected	O	O
sirolimus-treated	sirolimus-treated	O	O
patient	patient	O	O
with	with	O	O
psoriasis	psoriasis	O	S_disease
(	(	O	O
21	21	O	O
%	%	O	O
)	)	O	O
.	.	O	O

Activated	activated	O	O
peripheral	peripheral	O	O
blood	blood	O	O
T	t	O	O
cells	cells	O	O
from	from	O	O
patients	patients	O	O
with	with	O	O
psoriasis	psoriasis	O	S_disease
tended	tended	O	O
to	to	O	O
exhibit	exhibit	O	O
greater	greater	O	O
spontaneous	spontaneous	O	O
or	or	O	O
dexamethasone-induced	dexamethasone-induced	O	O
apoptosis	apoptosis	O	O
than	than	O	O
did	did	O	O
normal	normal	O	O
T	t	O	O
cells	cells	O	O
,	,	O	O
particularly	particularly	O	O
in	in	O	O
the	the	O	O
presence	presence	O	O
of	of	O	O
sirolimus	sirolimus	S_chemical	O
.	.	O	O

CONCLUSIONS	conclusions	O	O
:	:	O	O
Severe	severe	O	O
adverse	adverse	O	O
effects	effects	O	O
of	of	O	O
sirolimus	sirolimus	S_chemical	O
include	include	O	O
fever	fever	O	S_disease
,	,	O	O
anemia	anemia	O	S_disease
,	,	O	O
and	and	O	O
capillary	capillary	O	B_disease
leak	leak	O	I_disease
syndrome	syndrome	O	I_disease
.	.	O	O

These	these	O	O
symptoms	symptoms	O	O
may	may	O	O
be	be	O	O
the	the	O	O
result	result	O	O
of	of	O	O
drug-induced	drug-induced	O	O
apoptosis	apoptosis	O	O
of	of	O	O
lesional	lesional	O	O
leukocytes	leukocytes	O	O
,	,	O	O
especially	especially	O	O
activated	activated	O	O
T	t	O	O
lymphocytes	lymphocytes	O	O
,	,	O	O
and	and	O	O
possibly	possibly	O	O
release	release	O	O
of	of	O	O
inflammatory	inflammatory	O	O
mediators	mediators	O	O
.	.	O	O

Because	because	O	O
patients	patients	O	O
with	with	O	O
severe	severe	O	O
psoriasis	psoriasis	O	S_disease
may	may	O	O
develop	develop	O	O
capillary	capillary	O	O
leak	leak	O	O
from	from	O	O
various	various	O	O
systemic	systemic	O	O
therapies	therapies	O	O
,	,	O	O
clinical	clinical	O	O
monitoring	monitoring	O	O
is	is	O	O
advisable	advisable	O	O
for	for	O	O
patients	patients	O	O
with	with	O	O
inflammatory	inflammatory	O	O
diseases	diseases	O	O
who	who	O	O
are	are	O	O
treated	treated	O	O
with	with	O	O
immune	immune	O	O
modulators	modulators	O	O
.	.	O	O

